Literature DB >> 21216463

Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.

Sonal M Manohar1, Maggie J Rathos, Vinay Sonawane, Shalini V Rao, Kalpana S Joshi.   

Abstract

P276-00 is a novel cyclin-dependent kinase inhibitor especially potent for Cdk9-T1, Cdk4-D1 and Cdk1-B. Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of malignant plasma cells. Treatment of MM cell lines with P276-00 resulted in apoptosis that correlated with transcription inhibition and a significant decline in Mcl-1 protein levels with the appearance of cleaved PARP in these cells. In vivo studies of P276-00 confirmed antitumor activity in RPMI-8226 xenograft. These results suggest that P276-00 causes multiple myeloma cell death by disrupting the balance between cell survival and apoptosis through inhibition of transcription and downregulation of Mcl-1.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21216463     DOI: 10.1016/j.leukres.2010.12.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  26 in total

Review 1.  New molecular targets in mantle cell lymphoma.

Authors:  Samir Parekh; Marc A Weniger; Adrian Wiestner
Journal:  Semin Cancer Biol       Date:  2011-09-18       Impact factor: 15.707

2.  CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.

Authors:  Dharmalingam Subramaniam; Giridharan Periyasamy; Sivapriya Ponnurangam; Debarshi Chakrabarti; Aravind Sugumar; Muralidhara Padigaru; Scott J Weir; Arun Balakrishnan; Somesh Sharma; Shrikant Anant
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

3.  Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex.

Authors:  Jelena Randjelović; Slavica Erić; Vladimir Savić
Journal:  J Mol Model       Date:  2013-01-08       Impact factor: 1.810

4.  Molecular targeted approaches in mantle cell lymphoma.

Authors:  Marc A Weniger; Adrian Wiestner
Journal:  Semin Hematol       Date:  2011-07       Impact factor: 3.851

Review 5.  Emerging drug profile: cyclin-dependent kinase inhibitors.

Authors:  James S Blachly; John C Byrd
Journal:  Leuk Lymphoma       Date:  2013-07-29

Review 6.  Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.

Authors:  Prithviraj Bose; Gary L Simmons; Steven Grant
Journal:  Expert Opin Investig Drugs       Date:  2013-05-06       Impact factor: 6.206

7.  Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells.

Authors:  Laijun Xu; Lingzhi Li; Jun Zhang; Wenping Cai; Shouliang Zhao; Shangfeng Liu
Journal:  Odontology       Date:  2019-09-16       Impact factor: 2.634

8.  Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma.

Authors:  Prabha B Mishra; Aurelio S Lobo; Kalpana S Joshi; Maggie J Rathos; Gopinath A Kumar; Muralidhara Padigaru
Journal:  J Transl Med       Date:  2013-02-18       Impact factor: 5.531

9.  Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.

Authors:  Maggie J Rathos; Harshal Khanwalkar; Kavita Joshi; Sonal M Manohar; Kalpana S Joshi
Journal:  BMC Cancer       Date:  2013-01-23       Impact factor: 4.430

10.  P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

Authors:  Nitesh P Shirsath; Sonal M Manohar; Kalpana S Joshi
Journal:  Mol Cancer       Date:  2012-10-18       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.